ChemoCentryx Inc. agreed to pay $35 million to settle an investor class action over alleged false statements it made regarding the safety of its vasculitis drug.
The investors asked Judge Jon S. Tigar for preliminary approval of the settlement in a motion filed March 13 in the US District Court for the Northern District of California. The settlement will go to a class of more than 35,000 investors who acquired ChemoCentryx stock between November 2019 and May 2021. The investors alleged that during that time ChemoCentryx made false and misleading statements about the safety and efficacy of its avacopan drug ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.